Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

Abstract

MEK1/2 inhibitors are clinically approved for the treatment of BRAF-mutant melanoma, where they are used in combination with BRAF inhibitors, and are undergoing evaluation in other malignancies. Acquired resistance to MEK1/2 inhibitors, including selumetinib (AZD6244/ARRY-142866), can arise through amplification of BRAF^V600E or KRAS^G13D to reinstate ERK1/2 signalling. We have found that BRAF^V600E amplification and selumetinib resistance are fully reversible following drug withdrawal. This is because resistant cells with BRAF^V600E amplification become addicted to selumetinib to maintain a precise level of ERK1/2 signalling (2%-3% of total ERK1/2 active), that is optimal for cell proliferation and survival. Selumetinib withdrawal drives ERK1/2 activation outside of this critical “sweet spot” (~20%-30% of ERK1/2 active) resulting in a p57^KIP2-dependent G1 cell cycle arrest and senescence or expression of NOXA and cell death with features of autophagy; these terminal responses select against cells with amplified BRAF^V600E. ERK1/2-dependent p57^KIP2 expression is required for loss of BRAF^V600E amplification and determines the rate of reversal of selumetinib resistance. Growth of selumetinib-resistant cells with BRAF^V600E amplification as tumour xenografts also requires the presence of selumetinib to “clamp” ERK1/2 activity within the sweet spot. Thus, BRAF^V600E amplification confers a selective disadvantage or “fitness deficit” during drug withdrawal, providing a rationale for intermittent dosing to forestall resistance. Remarkably, selumetinib resistance driven by KRAS^G13D amplification/upregulation is not reversible. In these cells ERK1/2 reactivation does not inhibit proliferation but drives a ZEB1-dependent epithelial-to-mesenchymal transition that increases cell motility and promotes resistance to traditional chemotherapy agents. Our results reveal that the emergence of drug-addicted, MEKi-resistant cells, and the opportunity this may afford for intermittent dosing schedules (“drug holidays”), may be determined by the nature of the amplified driving oncogene (BRAF^V600E vs. KRAS^G13D), further exemplifying the difficulties of targeting KRAS mutant tumour cells.

Keywords

BRAF / CDKN1C/p57^KIP2 / EMT / ERK / KRAS / MEK / MEK inhibitor / resistance / selumetinib

References

[1] Holderfield M,McCormick F.Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond..Nat Rev Cancer2014;14:455-67 PMCID:PMC4250230

[2] Caunt CJ,Smith PD.MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road..Nat Rev Cancer2015;15:577-92

[3] Dombi E,Marcus LJ,Weiss B.Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas..N Engl J Med2016;375:2550-60 PMCID:PMC5508592

[4] Jänne PA,Barlesi F,Mazieres J.Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 Randomized Clinical Trial..JAMA2017;317:1844-53 PMCID:PMC5815037

[5] Carvajal RD,Kapiteijn E,Frank S.Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, Multicenter, Randomized Trial (SUMIT)..J Clin Oncol2018;36:1232-9

[6] Poulikakos PI,Bollag G,Rosen N.RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF..Nature2010;464:427-30 PMCID:PMC3178447

[7] Balmanno K,Gillings AS,Cook SJ.Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines..Int J Cancer2009;125:2332-41

[8] Corcoran RB,Bergethon K,Settleman J.BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF ^V600E mutation..Sci Signal2010;3:ra84 PMCID:PMC3372405

[9] Little AS,Sale MJ,Dry JR.Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells..Sci Signal2011;4:ra17

[10] Sale MJ.Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer..Biochem Soc Trans2014;42:776-83

[11] Sale MJ,Saxena J,Wojdyla K.MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification but KRAS amplification drives EMT/chemoresistance..Nat Commun2019;10:2030 PMCID:PMC6497655

[12] Chambard JC,Pouysségur J.ERK implication in cell cycle regulation..Biochim Biophys Acta2007;1773:1299-310

[13] Cook SJ,Gilley R.Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling..FEBS J2017;284:4177-95 PMCID:PMC6193418

[14] Cagnol S.ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence..FEBS J2010;277:2-21

[15] Sewing A,Lloyd AC.High-intensity Raf signal causes cell cycle arrest mediated by p21^Cip1..Mol Cell Biol1997;17:5588-97 PMCID:PMC232407

[16] Woods D,Cherwinski H,Lees E.Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21^Cip1..Mol Cell Biol1997;17:5598-611 PMCID:PMC232408

[17] Park JS,Gilfor D,Hylemon PB.A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes..Mol Biol Cell2000;11:2915-32 PMCID:PMC14965

[18] Lin AW,Stone JC,Serrano M.Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling..Genes Dev1998;12:3008-19 PMCID:PMC317198

[19] Zhu J,McMahon M.Senescence of human fibroblasts induced by oncogenic Raf..Genes Dev1998;12:2997-3007 PMCID:PMC317194

[20] Wang W,Liao R,Zhou JJ.Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence..Mol Cell Biol2002;22:3389-403 PMCID:PMC133789

[21] Serrano M,McCurrach ME,Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a..Cell1997;88:593-602

[22] Palmero I,Serrano M.p19ARF links the tumour suppressor p53 to Ras..Nature1998;395:125-6

[23] Ferbeyre G,Lin AW,McCurrach ME.Oncogenic ras and p53 cooperate to induce cellular senescence..Mol Cell Biol2002;22:3497-508 PMCID:PMC133786

[24] Ulisse S,Silvano G,Biordi L.Erk-dependent cytosolic phospholipase A2 activity is induced by CD95 ligand cross-linking in the mouse derived Sertoli cell line TM4 and is required to trigger apoptosis in CD95 bearing cells..Cell Death Differ2000;7:916-24

[25] Drosopoulos KG,Cermak L,Shirasawa S.Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway..J Biol Chem2005;280:22856-67

[26] Jo SK,Sung SA,Won NH.MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis..Kidney Int2005;67:458-66

[27] Tewari R,Koul N.Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation..J Neurochem2008;107:616-27

[28] Shenoy K,Pervaiz S.LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors..Cancer Res2009;69:1941-50

[29] Sheridan C,Elgendy M,Martin SJ.An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs..Oncogene2010;29:6428-41

[30] Elgendy M,Brumatti G.Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival..Mol Cell2011;42:23-35

[31] Emery CM,Zipser MC,Niu L.MEK1 mutations confer resistance to MEK and B-RAF inhibition..Proc Natl Acad Sci USA2009;106:20411-6 PMCID:PMC2777185

[32] Yang J,Marr BP.Treatment of uveal melanoma: where are we now?.Ther Adv Med Oncol2018;10:1-17 PMCID:PMC5824910

[33] Thiery JP,Huang RY.Epithelial-mesenchymal transitions in development and disease..Cell2009;139:871-90

[34] Shin S,Yoon SO,Blenis J.ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events..Mol Cell2010;38:114-27 PMCID:PMC2854677

[35] Ichikawa K,Nakamura T,Tomida T.MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during epithelial-mesenchymal transition by regulating the co-repressor CtBP..Mol Cell2015;58:35-46

[36] Weiss MB,Mayberry MM,Berger AC.TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells..Cancer Res2012;72:6382-92 PMCID:PMC3531871

[37] Ye X.Epithelial-mesenchymal plasticity: a central regulator of cancer progression..Trends Cell Biol2015;25:675-86 PMCID:PMC4628843

[38] Fischer KR,Lee S,Li F.Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance..Nature2015;527:472-6 PMCID:PMC4662610

[39] Zheng X,Kim J,Kaye J.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer..Nature2015;527:525-30 PMCID:PMC4849281

[40] Unni AM,Oh MH,Ferrarone JR.Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells..Elife2018;7:e33718 PMCID:PMC6298772

[41] Kennedy AL,Manoharan I,Jamieson NB.Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis..Mol Cell2011;42:36-49 PMCID:PMC3145340

[42] Fruman DA,Hopkins BD,Cantley LC.The PI3K pathway in human disease..Cell2017;170:605-35 PMCID:PMC5726441

[43] Manning BD.AKT/PKB signaling: navigating the network..Cell2017;169:381-405 PMCID:PMC5546324

[44] Kavanagh E.The hallmarks of CDKN1C (p57, KIP2) in cancer..Biochim Biophys Acta2011;1816:50-6

[45] Figliola R,Vaccarello G.Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation..J Mol Biol2008;380:265-77

[46] Pateras IS,Niforou K,Gorgoulis VG.p57KIP2: "Kip"ing the cell under control..Mol Cancer Res2009;7:1902-19

[47] Schlicker A,Chresta CM,Pritchard A.Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines..BMC Med Genomics2012;5:66 PMCID:PMC3543849

[48] Xu W,Lu N.A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition..Cell Adh Migr2015;9:317-24 PMCID:PMC4594353

[49] Ansieau S,Doreau A,Bouchet BP.Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence..Cancer Cell2008;14:79-89

[50] Liu Y,Darling DS,Dean DC.Zeb1 links epithelial-mesenchymal transition and cellular senescence..Development2008;135:579-88 PMCID:PMC2507753

[51] Ohashi S,Wong GS,Grugan KD.Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors..Cancer Res2010;70:4174-84 PMCID:PMC3007622

[52] Singh A.EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer..Oncogene2010;29:4741-51 PMCID:PMC3176718